Previous close | 1.1400 |
Open | 1.1100 |
Bid | 0.9801 x 800 |
Ask | 1.1900 x 1100 |
Day's range | 1.1100 - 1.1900 |
52-week range | 0.8100 - 3.3300 |
Volume | |
Avg. volume | 24,456 |
Market cap | 9.586M |
Beta (5Y monthly) | 0.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.3400 |
Earnings date | 30 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude MedicalTEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2022 financial results on Thursday, March 30, 2023, before the financial markets open. Management will host a conference call and webcast with the investment co
Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketingTEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North America and Vice President of Global Marketing. Mr. Gleason brings to InspireMD signi